Since NAD+ levels are important in determining the fate of a cancer cell to surviving a therapy, we examined if the protein NAMPT, the rate-limiting enzyme in NAD biosynthesis, played a role in a cancer cell line resistance to metformin treatment. The gene discussed is NAMPT; the disease is cancer.